Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims Analysis
DRF-treated patients with MS had a significantly lower risk of SI compared with anti-CD20-treated patients, with no difference in ARR. More real-world studies are needed to understand the efficacy and safety of DMTs in the setting of de-escalation in aging patients with MS.
Authors
- Ivan Božin (ORCID: https://orcid.org/0009-0008-2205-4233)
- Tony J. C. Wang (ORCID: https://orcid.org/0000-0001-5809-3025)
- Jonathan Douglas Santoro (ORCID: https://orcid.org/0000-0002-8350-8234)
- Derrick Robertson (ORCID: https://orcid.org/0000-0001-8993-0981)
- Sai L. Shankar (ORCID: https://orcid.org/0000-0003-3249-8360)
- Rebecca Straus Farber
- Boyang Bian (ORCID: https://orcid.org/0000-0003-0153-4218)
- Erica Goff
- Michelle Betz
- Yang Mao-Draayer
- Daniel Gomes
- James B. Lewin
- Le H. Hua
- Mark Gudesblatt
- Nicholas Belviso
- Ahmed Z. Obeidat
- Jason P. Mendoza
Institutions
- Biogen (United States) (US)
- Cleveland Clinic (US)
- Children's Hospital of Los Angeles (US)
- Medical College of Wisconsin (US)
- University of South Florida (US)
- Columbia University Irving Medical Center (US)
- Lou Ruvo Brain Institute (US)
- University of Alabama System (US)
- Oklahoma Medical Research Foundation (US)
- University of Alabama at Birmingham (US)
- Bioanalytica (Switzerland) (CH)
- Urology Associates (US)
- Biogen (Switzerland) (CH)
- Sentara Virginia Beach General Hospital (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1007/s12325-025-03480-5
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Biogen